Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality?

K. Koehorst-ter Huurne, K. Movig, P. VanderValk, J. Van der Palen, M. Brusse-Keizer (Enschede, Netherlands)

Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Session: New clinical evidence for asthma and COPD treatments
Session type: Thematic Poster Session
Number: 2419
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Koehorst-ter Huurne, K. Movig, P. VanderValk, J. Van der Palen, M. Brusse-Keizer (Enschede, Netherlands). Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality?. Eur Respir J 2014; 44: Suppl. 58, 2419

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD?
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016

The adherence to inhaled drugs in COPD patients: Effect on survival
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015

Differences in adherence to common inhaled medications in COPD
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013


Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


One-year mortality associated with COPD treatment: A comparison of tiotropium and long-acting beta-2-agonists
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014


The influence of type of inhalation device on adherence of COPD patients to inhaled medication
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013


Association between inhaled corticosteroid use in COPD and incidence or worsening of type2 diabetes
Source: International Congress 2014 – Markers
Year: 2014


Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

Safety of tiotropium in renally impaired patients
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Hospital treatment costs of exacerbations in COPD patients with indications for LTOT
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015


Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Use of long acting bronchodilators and inhaled corticosteroids within 30-days of discharge in older adults hospitalized for AECOPD
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015